Member Info for Brighty1

73% Up now. However, it's not really about the rise today it's more about confidence in the company being restored in front of key clients, Governments and ofcourse the stock market / investors. Over the next few months we should see a sustained rise in the share price. Plus don't forget as an extra point that as the court case has been settled the Gov't will be free to award ABDX contracts. Now remind me who has an AntiBody Test that the Gov't are interested in and a huge UK manufacturing facility for Lateral Flow Tests? oh, yes...ABDX. Good luck, Brighty

I'm not at all surprised to see the share price rise over 50% today. What many investors are starting to factor in is the potential enterprise value of the ABDX business once this court case is done and dusted. A huge cloud will be lifted and any trade suitors or major potential clients will then be more likely to deal with ABDX, including the UK Govt. From an M&A perspective what has always interested me about the low value of ABDX is the takeover potential when you look at the sale last year of Wales based diagnostics and life sciences business BBI, which was sold for £400 million (x30 of our current mcap). Remember, we IPO'd 18 months ago at £100m (x 10 of our current mcap). Then there's the placing at 25p, significant Director buys and the fact that the testing industry is only going to grow and that Covid is still around. The IPO enabled investment in the business and ABDX is on the launch pad ready to produce hundreds of millions of various tests, both Covid and non-Covid. That's why I have pencilled in an initial 48p-55p a share as a more appropriate share price on the back of the above prior to moving up to over 100 pence a share. It is clear that there are lots of reasons to invest in ABDX moving forward. Today, hopefully, is the start of better days for our share price. We will know the court case result in under 2 hrs.

Good luck, Brighty

For a bit of perspective and balance it is also worth stating that AIM companies raise and raise to achieve their goals and our investment either pans out or it does not. That's the nature of the AIM beast. Everyone has their own investment strategies and for what it's worth there's nothing worrying me about MOS for a medium - long hold. 3 years down the line if the NFT deals come off as we hope and expect and are producing revenue and profits I have little doubt this will be 15p+a share. The early raises to maximise the opportunities will then have been very much worth it. This is not a short term project. Investing in a share for years is an approach that has worked well with small caps on AIM that are reminiscent to MOS re their fund raising antics. I can name SAR, TEK, TXP, PXEN, WEB, NCYT, SNG, GGP as just a few that have taken years to come to fruition but that have given investors like me a superb return despite many fund raises to get from A-B. I'm of the same opinion with the likes of MOS, GFIN, GDR, BOIL, TYM and a few other AIM minnows that are raising to enable them to be at the cutting / edge of their respective sectors. All I can tell the doubters - and who knows they might be right - is that AIM co's like MOS are risk investments but that if they come good such as Sareum, Tek Capital, Touchstone, Prospex, Webis, Greatland, Novacyt, Synairgen etc then it is worth the wait. Good luck MOS investors and lets see where our share price is in 3 years.... Brighty

Interesting to note that EUZ has announced today via RNS a proposed US$6m Farm-In Arrangement with Denarius Metals Corp for up to 80% of its Toral Project. If TYM can pull off something similar for Jacks with FQM or ANother this would be the tipping point required for the share price to sky rocket. Good luck, Brighty

Here's why a major global pharmaceutical company such as Johnson & Johnson, Roche, Novartis, Merck, AbbVie, GSK, Bristol Myers Squibb, Pfizer etc will be very very interested in our point of care device for stroke management: The global $troke diagnostic and therapeutic market size is projected to exceed over $65.6 billion USD by 2030.Globally 1 in 4 adults over the age of 25 will have a stroke in their lifetime. 12.2 million people worldwide will have their first stroke this year and 6.5 million will die as a result. Over 110 million people in the world have experienced a stroke.

https://www.world-stroke.org/world-stroke-day-campaign/why-stroke-matters/learn-about-stroke#:~:text=Over%20110%20million%20people%20in%20the%20world%20have%20experienced%20stroke.

That's why it's looking increasingly exciting for GDR shareholders. As you can see above the global stroke market is massive plus we have two other very attractive propositions with our MT-RNR1 test for AIHL and POC COVID-19 test. Happy days!

Good luck, Brighty

You are quite right, a bid for GDR is a real possibility. We have a number of significant commercial opportunities which big pharma will be very interested in. e.g. 1. MT-RNR1 test for AIHL. 2. Point of Care device for stroke management 3. POC COVID-19 test. GDR operates in a very acquisitive sector where mega licencing and takeover deals happen for late stage / phase 2-3 small co's (just like GDR). What price would GDR be valued at? Heres a couple of small cap deals to wet your appetite:

* Last year Sanofi acquired Kymab for an upfront payment of approximately $1.1 billion plus $350 million in milestones.
* This year GSK acquired Sierra Oncology for $1.9 billion

The following information is also worth noting:

* The pharma sector recorded 182 M&A deals worth $30 billion in Q2 2022, a 67% increase in deal value.
* In the last 12 months there were 27 deals in the Genomics space and 19 deals in the cell and gene therapy space.

https://www.pharmaceutical-technology.com/deals-insights/

GDR's MT-RNR1 test for AIHL, Point of Care device for stroke management & POC COVID-19 test will certainly be of interest to big pharmaceutical companies. It is just whether it will be a licencing deal or a takeover deal....

Good luck, Brighty

I agree Baserite on the HNWI. It had a dramatic impact at SAR for many investors. I thought I recognised your name from the SAR board. I had bought in at 0.4 and sold a chunk at just over x20 at 8p and still holding quite a few even after the consolidation there as I expect further gains. Mind you, it took a good decade to achieve. i.e. patience was required but the reward in the ISA was worth it. GDR interests me in the same way as it has a number of big commercial opportunities to strike gold. e.g. 1. MT-RNR1 test for AIHL. 2. Point of Care device for stroke management 3. POC COVID-19 test. My take on investing is to take a medium to long term view. That's what I'm doing with GDR as the gains could be stratospheric with a licencing deal or takeover deal. Investing over the medium term has worked for me on numerous occasions with smaller plcs such as TEK, SAR, TXP, WEB, PXEN, FEN, IQE,SFOR, GGP, SNG,NCYT etc. Some have boomed and crashed back down and luckily I've top sliced but I'm still invested in all of these and many others as my due dilligence / research is what brought me to invest in these companies initially. I tend to buy stocks at the forefront / cutting edge of their sectors. The risk is significant but so have been the gains. I can see the same rationale for investing in GDR that drew me to the stocks named above. The RNS today from GDR about the FDA submission for our MT-RNR1 product is a great example of a medium term investment strategy in my opinion. GDR is confirming that it is getting its ducks in a row and I'm happy with that as in the medium term this will create significant shareholder value if the USA backs it and the company start confirming orders. It will then be licencing or takeover time. That's when we will realise our true value. The monthly gains and declines don't interest me. It's what's at the end of the GDR rainbow that gets me excited. So, I tend to agree with you that a few HNWI's buying into GDR would and could be the next obvious step as our mcap is tiny and it would be chicken feed. Good luck, Brighty

When you focus on the humongous amounts of cash being paid by major pharmas for takeover deals (& licencing) it just demonstrates that N4P shareholders could be in the right space at the right time with the successful in vitro testing of Nuvec. What we also know is that the N4P 12 month high was over 9p and that a x 10 “bagger” only values N4P under £50 million. We operate in a multi billion takeover sector and if Nigel Theobald and the team at N4P get this right N4P will be valued accordingly at very much more than £50 million. Good luck, Brighty

I totally agree. For those invested with an eye on the final prize it is worth pointing out that a major pharmaceutical player would be able to upscale SNG001 globally much quicker than Synairgen ever could. It's a major licencing deal or takeover for me in due course. A reminder that a few months ago GSK announced it was to acquire late-stage bio minnow Sierra Oncology for $1.9bn. i.e. Deals for phase 2/3 small pharmas are often in the hundreds if not billions. Synairgen's current Mcap is peanuts. Therefore, a takeover of SNG can not be ruled out bearing in mind the vast amounts of cash being stockpiled by the major players in the pharma sector at the moment. Good luck, Brighty

Yes Car365, hold for 3 years and this share could be very rewarding indeed. MOS is a really exciting investment and you are quite right about a serious multibag opportunity. 1p + a share is certainly achievable this year and once people realise the magnitude of what is happening at MOS and in this sector generally don't rule out 15p a share by the end of 2025. i.e. Take a position and then wait a couple of years for the share to multibag significantly. Right sector. Right time. Good luck, Brighty

Yes, that is what we all wanted to hear: "successful in vitro testing of Nuvec" and that N4P is to now commence commercial discussions on the back of this. If this pans out our value is going to sky rocket. It's a waiting game. Good luck, Brighty

Looks like the board are getting the MGC house in order. This has to be encouraging news for shareholders after a turbulent few months. Remember, the science and data announcements over the last year on inflammatory diseases, Covid, cognitive disorders and brain cancer all look first rate. Hopefully it is turnaround time now and we will start to see shareholder value created.

Highlights from the RNS today:

* Appointment of new COO/Deputy CEO announced today

* plus Investor Update - 11th October

* "The Company advises that it has appointed Ms Yifat Steuer as the Company's new Chief Operating Officer/Deputy CEO, with Ms Steuer having been previously engaged as an advisor to the executive team during 2022.

* Ms Steuer has over 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson and GlaxoSmithKline, as well experience working with SMEs and start-ups.

* Ms Steuer is a qualified Chartered Accountant and holds an MBA degree from Bayes Business School - University of London. Ms Steuer will work closely with CEO Roby Zomer to execute on MGC Pharma's business strategy, utilising her experience in in pharmaceuticals, manufacturing, logistics, medical technology and digital health".

Plus..."The Company also advises that Mr Brett Mitchell's role as Chairman of the Company's board of directors has transitioned from an executive to a non-executive position, to be more in line with corporate structuring of UK listed companies".

That's what investors want to hear....

Good luck, Brighty

An 86% relative risk reduction in hospitalisation following treatment with SNG001 is excellent news plus the fact that a larger Phase 3 clinical trial is the next step. Which major global pharma will be first to licence SNG001? It looks more and more positive that this will happen now. Good luck, Brighty

Interesting to note that Sanderson Capital Partners has increased its holding in TYM from 3.26% to 10.45% in 2022.
Good luck, Brighty

Rome wasn't built in a day and if your are investing for the medium term here's a good reminder of what the New Scientist article highlighted about GDR's huge potential a few months ago. Check out the summary below. The full article link is at the foot of this post. It's certainly worth a read to reinforce the huge potential of GDR as an investment in the medium term:

Highlights from the article:

* Occasionally, children go deaf as a result of antibiotic treatment. Now a rapid genetic test has been launched to identify those who are vulnerable to such ear damage, so that alternative antibiotics can be given.

* The test delivers a result in 26 minutes, meaning it can be done quickly enough to guide what to do for babies with suspected sepsis, who need treatment as fast as possible.

* About one in 500 people have a genetic mutation that means that the antibiotic gentamicin kills cells inside their ear. This is thought to cause about 14,000 people worldwide to go permanently deaf each year.

* To check for the genetic mutation, most hospitals currently use PCR-based tests, which can take days to return results. Guidance for treating babies with suspected sepsis in hospitals in England says antibiotics should be started within 1 hour of doctors recognising that treatment is needed.

* The assay, which Manchester University NHS Foundation Trust hospitals has started using routinely, is faster because it uses a different genetic testing technique, called RT-LAMP. Made by UK firm Genedrive, the test was used in two UK hospitals. Of 526 babies who needed treatment for suspected sepsis, the test failed to produce a result in 17 per cent of cases, but it identified three babies with the mutation that put them at risk of deafness, who all received the alternative antibiotic, according to a recently published trial. “We have got three people that will go through life with their hearing intact that would have been deaf if they had not had this [test], says David Budd at Genedrive.

See the full article at:

https://www.newscientist.com/article/2314445-genetic-test-for-mutation-that-leads-to-antibiotic-induced-deafness/?utm_medium=social&utm_campaign=echobox&utm_source=Twitter#Echobox=1648798606

It's worth reminding the impatient and or newbies wishing to research GDR that we are invested in a breakthrough genetic test which gives results in half an hour to show if a person may become deaf in response to certain antibiotics. This is big news in our sector and eventually GDR will be valued accordingly.

Good luck, Brighty

Well, "significant copper mineralisation intersected in all four diamond drillholes" is certainly very encouraging. Remember, that TYM has received positive results from the drill programme at Jacks, so this is likely to get interesting here. Good luck, Brighty

Gate13Boy, your last 2 posts were brilliant and very refreshing. Well said. The IMF intervention was a disgrace and very biased. The budget plan is clearly growth positive and as you quite rightly say the same applies to all the other deregulatory and tax initiatives the PM is working on and she and the Govt need to enact them. There are many globalists who won't like what the UK is planning to do and no doubt hoped for a higher Corporation tax here. The lower the tax the more inward investment the UK will get. We will then see the economy grow and that will have a positive impact for investors. Good luck, Brighty

For what it’s worth there is a clear-cut correlation between the kind of policy announced by the Govt/BOE and a rising stock market once the negative headlines die down. In fact, some of the biggest stock market gains in history have occurred when a Government supports or even jumpstarts economic activity. I'm in Lloy at 31p a share and expect to more than double my investment. i.e. 85p+ a share in the next 12-18 months as a minimum on the back of a rising stock market galvanised by Gov't/central bank activity. Good luck, Brighty

The IQE takeover talk appears to be gathering pace and is perhaps particularly interesting following last years collaboration with GlobalFoundries. IQE at the time said that it "marked a step change for the company". At the time of the collaboration announcement it was pretty clear that GF had recognised the quality of IQE's market-leading GaN products to help it upscale its own business, therefore it would make strategic sense for a player such as GF to buy IQE. Quite often M&A activity follows such a collaboration as it gives both parties an opportunity to work together before a takeover / merger is formally announced. One to watch. Good luck, Brighty

Here's the RNS just published thismorning. TYM looks to be gearing up in Zambia for news and the FQM joint announcement a couple of weeks ago is certainly creating interest again and a buzz about what they are hoping to achieve in Zambia. ....Good luck, Brighty

APPOINTMENT OF EXPLORATION MANAGER, ZAMBIA

Tertiary Minerals plc is pleased to announce that it has retained the services of Richard Belcher as its Exploration Manager for Zambia.

Richard is a multi-commodity, multi-disciplined explorationist with a strong technical background and 19 years' post-PhD experience across all stages of exploration with an emphasis on gold and base metals in Africa, including in Zambia.

He has a proven capability from reconnaissance through to resource stage in challenging environments and was most recently a senior consulting geologist to Altus Strategies before its recent merger with Elemental Royalties.

Richard holds a BSc (Hons) Exploration Geology from Cardiff University (UK) and a PhD from Stellenbosch University (RSA) and is a Chartered Geologist and Fellow of the Geological Society of London.

Commenting today, Executive Chairman Patrick Cheetham said:

"This is a key appointment for the Company as we ramp up our exploration in Zambia. Richard will be leading the collaboration with major Zambian copper producer First Quantum Minerals that we announced earlier this month.

We look forward to working with Richard and with FQM and to our first joint technical meeting with FQM which is due to be held next week."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.